Study guide
3.3 Central Nervous System & Antimicrobial Pharmacology
PSI Equivalence Examination Third Country Qualification Recognition
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & TCQR Framework
1.1 TCQR Pathway and PSI Equivalence Exam Structure 1.2 PSI Core Competency Framework and MPharm Standard 1.3 Irish Healthcare System & Pharmacy Environment
2 Chapter 2: Pharmaceutical Calculations
2.1 Paediatric & Adult Dose Calculations 2.2 Percentage Strengths, Ratio Strengths & PPM Conversions 2.3 Dilutions, Alligations & Reconstitution 2.4 Infusion Rates, Syringe Drivers & Opioid Equianalgesic Conversions
3 Chapter 3: Pharmacology & Applied Pharmacokinetics
3.1 Receptor Pharmacology & Autonomic Nervous System 3.2 Cardiovascular & Renal Pharmacology 3.3 Central Nervous System & Antimicrobial Pharmacology 3.4 Pharmacokinetics & Narrow Therapeutic Index Drugs
4 Chapter 4: Basic Science & Pharmaceutics
4.1 Physicochemical Properties of Drugs 4.2 Dosage Form Formulation & Excipients 4.3 Drug Stability, Degradation & Bioequivalence
5 Chapter 5: Pharmacy Practice & Dispensing Workflow
5.1 Prescription Validation & Dispensing Workflow 5.2 Patient Counselling & Medicines Safety 5.3 Responding to Symptoms & Minor Ailments 5.4 Primary Care Schemes & Community Services
6 Chapter 6: Irish Pharmacy Law & Professional Ethics
6.1 Pharmacy Act 2007 & PSI Governance 6.2 Medicinal Products Regulations 6.3 Controlled Drugs Legislation & Misuse of Drugs Regulations 6.4 Professional Ethics & Code of Conduct
7 Chapter 7: Clinical Therapeutics & Disease State Management
7.1 Respiratory & Endocrine Therapeutics 7.2 Cardiovascular & Gastrointestinal Therapeutics 7.3 Infections, Antimicrobial Stewardship & Public Health 7.4 Special Populations & Complex Care
8 Chapter 8: OSCE & Practical Clinical Communication Skills
8.1 OSCE Station Structure & Core Competencies 8.2 Structured Patient Consultations & Devices Counselling 8.3 Prescriber Interventions, Ethical Dilemmas & Professional Judgement
3.3 Central Nervous System & Antimicrobial Pharmacology
Key Takeaways Explain This Topic AI
Paracetamol hepatotoxicity during overdose results from saturation of phase II glucuronidate/sulfate pathways, producing toxic N-acetyl-p-benzoquinone imine (NAPQI) which depletes hepatic glutathione; prompt administration of N-acetylcysteine (NAC) restores glutathione stores.
Opioid analgesics act as full agonists at mu (μ) opioid receptors to modulate pain perception, but carry risks of life-threatening respiratory depression, sedation, constipation, and miosis, rapidly reversible with intravenous naloxone.
Selective serotonin reuptake inhibitors (SSRIs) increase synaptic serotonin by inhibiting SERT; combining SSRIs with MAOIs, linezolid, or tramadol can precipitate fatal Serotonin Syndrome characterized by neuromuscular hyperreactivity, autonomic instability, and altered mental status.
Beta-lactam antibiotics (penicillins, cephalosporins, carbapenems) inhibit penicillin-binding proteins (PBPs) to disrupt peptidoglycan cell wall synthesis, exhibiting time-dependent bactericidal activity.
Methicillin resistance in Staphylococcus aureus (MRSA) is mediated by the mecA gene, which encodes an altered penicillin-binding protein (PBP2a) with low affinity for all conventional beta-lactam antibiotics.
Last updated: July 2026
3.3 Central Nervous System & Antimicrobial Pharmacology
Quick Reference: Central nervous system (CNS) agents modify neurotransmitter kinetics to manage pain, psychiatric disorders, and seizures. Antimicrobial chemotherapy targets structural or metabolic differences between pathogens and host cells to eliminate bacterial, fungal, and viral infections without host toxicity.
Effective therapeutic management requires precise understanding of CNS receptor targets, metabolic toxicity pathways, antimicrobial mechanism classifications, and resistance mechanisms.
Analgesics: Non-Opioid & Opioid Mechanisms
Pain management is organized hierarchically using the WHO analgesic ladder, starting with non-opioid analgesics and progressing to weak and strong opioids.
Paracetamol (Acetaminophen)
Mechanism: Central inhibition of cyclooxygenase (COX-3 / COX-1 variant) and active cannabinoid system modulation ( A M 404 AM404 A M 404 active metabolite). Lacks peripheral anti-inflammatory activity.
Overdose & Hepatotoxicity:
Normal therapeutic doses undergo Phase II glucuronidation (60%) and sulfation (35%).
In overdose (>75–150 mg/kg), Phase II pathways saturate. Metabolism shifts to CYP2E1/CYP1A2, producing N-acetyl-p-benzoquinone imine (NAPQI) .
When intracellular glutathione stores deplete below 30%, NAPQI binds covalently to hepatic parenchymal proteins, causing acute centrolobular hepatic necrosis .
Antidote: N-acetylcysteine (NAC) provides cysteine for glutathione regeneration and directly conjugates NAPQI. Most effective within 8 hours of ingestion.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Mechanism: Inhibit cyclooxygenase (COX-1 and COX-2) enzymes, preventing conversion of arachidonic acid to prostaglandins ( P G E 2 , P G I 2 PGE_2, PGI_2 PG E 2 , PG I 2 ) and thromboxane.
Non-Selective (Ibuprofen, Naproxen, Diclofenac): Inhibit COX-1 and COX-2.
COX-2 Selective (Celecoxib, Etoricoxib): Preserve COX-1 homeostatic functions (gastric protection, platelet function) while reducing inflammation. Cardiovascular Risk: Imbalance between endothelial P G I 2 PGI_2 PG I 2 (inhibited) and platelet T X A 2 TXA_2 TX A 2 (uninhibited) increases atherothrombotic event risk.
Adverse Effects: Gastric mucosal ulceration, acute kidney injury (due to loss of compensatory P G E 2 PGE_2 PG E 2 -mediated afferent arteriolar vasodilation), sodium and water retention, exacerbation of asthma.
Opioid Analgesics
Opioid Receptors: μ \mu μ (Mu), κ \kappa κ (Kappa), δ \delta δ (Delta)—all G i G_i G i -protein coupled. Activation decreases intracellular cAMP, closes presynaptic voltage-gated C a 2 + Ca^{2+} C a 2 + channels (inhibiting neurotransmitter release), and opens postsynaptic K + K^+ K + channels (hyperpolarization).
Agents: Morphine, Oxycodone, Fentanyl, Buprenorphine (partial agonist), Methadone, Codeine, Tramadol (weak μ \mu μ -agonist + SERT/NET inhibitor).
Opioid Toxidrome: Sedation, respiratory depression (decreased sensitivity of brainstem chemoreceptors to CO 2 \text{CO}_2 CO 2 ), pinpoint pupils ( miosis ), constipation, nausea, pruritus (histamine release).
Reversal: Naloxone (competitive antagonist; short half-life requires repeated administration to prevent re-narcotisation).
- Psychotropic Agents & Neurotransmitter Modulation
- Antidepressants
SSRIs (Sertraline, Fluoxetine, Citalopram, Escitalopram): First-line. Block serotonin transporter (SERT). Adverse effects: GI upset, sexual dysfunction, hyponatremia (SIADH), QT prolongation (citalopram).
SNRIs (Venlafaxine, Duloxetine): Block SERT and NET. Useful in comorbid neuropathic pain.
Tricyclic Antidepressants (TCAs: Amitriptyline, Nortriptyline): Block SERT/NET plus α 1 \alpha_1 α 1 , M 1 M_1 M 1 , H 1 H_1 H 1 receptors. Overdose Lethality: Cardiac sodium channel blockade causes QRS prolongation, ventricular arrhythmias, hypotension, and seizures. Treated with IV sodium bicarbonate.
Serotonin Syndrome: Co-administration of serotonergic agents (SSRIs, MAOIs, tramadol, linezolid, MDMA). Features: Hyperreflexia, clonus, autonomic instability, hyperthermia. Treatment: Supportive care, Cyproheptadine (5-HT antagonist).
Anxiolytics & Hypnotics
Benzodiazepines (Diazepam, Lorazepam, Midazolam, Alprazolam): Positive allosteric modulators of GABA A \text{GABA}_A GABA A receptors. Increase the frequency of Cl − \text{Cl}^- Cl − channel opening → \rightarrow → membrane hyperpolarization. Antidote: Flumazenil (risk of precipitating withdrawal seizures in dependent patients).
Z-Drugs (Zopiclone, Zolpidem): Selective binding to α 1 \alpha_1 α 1 -subunit of GABA A \text{GABA}_A GABA A receptor for hypnotic action with less muscle relaxation.
Antipsychotics
Typical / First-Generation (Haloperidol, Chlorpromazine): High D 2 \text{D}_2 D 2 receptor antagonism. Effective for positive symptoms; high risk of Extrapyramidal Symptoms (EPS) (dystonia, akathisia, parkinsonism, tardive dyskinesia) and hyperprolactinemia.
Atypical / Second-Generation (Olanzapine, Risperidone, Quetiapine, Clozapine): Dual 5 − HT 2 A 5-\text{HT}_{2A} 5 − HT 2 A and D 2 \text{D}_2 D 2 antagonism. Lower EPS risk; high risk of metabolic syndrome (weight gain, dyslipidemia, diabetes).
Clozapine: Gold standard for treatment-resistant schizophrenia. Unique adverse effect: Agranulocytosis (1-2%), requiring mandatory baseline and ongoing full blood count (FBC) monitoring.
Antiepileptic Drugs (AEDs)
Antiepileptics suppress focal or generalized seizure activity by modulating voltage-gated ion channels or enhancing GABAergic inhibition.
Carbamazepine: Blocks voltage-gated Na + \text{Na}^+ Na + channels. Powerful inducer of CYP3A4 (auto-induction). Screening for HLA-B*1502 allele required in Asian ancestry due to Stevens-Johnson Syndrome (SJS) risk.
Lamotrigine: Blocks Na + \text{Na}^+ Na + and Ca 2 + \text{Ca}^{2+} Ca 2 + channels. Requires slow dose titration to avoid life-threatening toxic epidermal necrolysis (TEN).
Sodium Valproate: Broad-spectrum. Blocks Na + \text{Na}^+ Na + channels, T-type Ca 2 + \text{Ca}^{2+} Ca 2 + channels, and increases GABA. Highly teratogenic (neural tube defects, cognitive impairment; prohibited in pregnancy unless no alternative exists).
Levetiracetam: Binds synaptic vesicle protein SV2A , inhibiting neurotransmitter exocytosis. Minimal CYP interactions; excreted renally.
Antibacterial Classes & Antimicrobial Resistance
Class Representative Agents Mechanism of Action Spectrum & Key Indications Major Toxicity / Cautions
β \beta β -Lactams Penicillins, Cephalosporins, Carbapenems, Monobactams Bind Penicillin-Binding Proteins (PBPs), inhibiting peptidoglycan cell wall cross-linking ( D -Ala- D -Ala D\text{-Ala-}D\text{-Ala} D -Ala- D -Ala ). Bactericidal ( T > MIC T > \text{MIC} T > MIC ) Broad spectrum depending on generation. Carbapenems cover ESBL producers Hypersensitivity/anaphylaxis, seizures at high doses (imipenem)
Glycopeptides Vancomycin, Teicoplanin Binds D -Ala- D -Ala D\text{-Ala-}D\text{-Ala} D -Ala- D -Ala terminus of cell wall precursor, blocking transglycosylation Gram-positive only (MRSA, C. difficile oral) Nephrotoxicity, ototoxicity, Red Man Syndrome (flushing due to non-immune histamine release)
Macrolides Azithromycin, Clarithromycin, Erythromycin Binds 50S ribosomal subunit, inhibiting translocation. Bacteriostatic Atypical pneumonia ( Legionella, Mycoplasma ), H. pylori QT prolongation, cholestatic jaundice, strong CYP3A4 inhibition
Aminoglycosides Gentamicin, Tobramycin, Amikacin Binds 30S ribosomal subunit, causing mRNA misreading. Bactericidal ( C max / MIC C_{\text{max}}/\text{MIC} C max / MIC ) Severe Gram-negative aerobic infections ( Pseudomonas ) Irreversible ototoxicity , reversible nephrotoxicity (acute tubular necrosis)
Fluoroquinolones Ciprofloxacin, Levofloxacin Inhibits DNA Gyrase (Topoisomerase II) and Topoisomerase IV. Bactericidal Gram-negative, respiratory tract, complicated UTI Tendinitis/tendon rupture, QT prolongation, aortic aneurysm risk, chelation with divalent cations
Tetracyclines Doxycycline, Minocycline Binds 30S ribosomal subunit, blocking aminoacyl-tRNA entry. Bacteriostatic Atypical infections, Lyme disease, acne, malaria prophylaxis Tooth discoloration in children <8 yrs, photosensitivity, esophageal ulceration
Mechanisms of Bacterial Resistance
Enzymatic Inactivation: Production of β \beta β -lactamases (penicillinases, ESBLs, AmpC, carbapenemases) that hydrolyze the β \beta β -lactam ring.
Target Modification: Alteration of binding site (e.g., mecA gene in MRSA encoding PBP2a with low β \beta β -lactam affinity; vanA gene in VRE altering target to D -Ala- D -Lactate D\text{-Ala-}D\text{-Lactate} D -Ala- D -Lactate ).
Efflux Pumps: Active transport of antibiotic out of bacterial cytoplasm (e.g., fluoroquinolone and tetracycline resistance in Gram-negative bacilli).
Decreased Permeability: Porin channel loss or down-regulation in outer membrane ( Pseudomonas aeruginosa carbapenem resistance).
- Antifungals & Antivirals
- Antifungal Agents
Azoles (Fluconazole, Voriconazole, Itraconazole): Inhibit 14 α \alpha α -demethylase (CYP51), blocking ergosterol synthesis. Inhibits human CYP450 enzymes.
Polyenes (Amphotericin B, Nystatin): Bind directly to fungal ergosterol, forming transmembrane pores that leak intracellular K + \text{K}^+ K + and Mg 2 + \text{Mg}^{2+} Mg 2 + . Lipid formulations reduce nephrotoxicity.
Echinocandins (Caspofungin, Micafungin): Inhibit β \beta β -(1,3)- D D D -glucan synthase, disrupting fungal cell wall integrity.
Antiviral Therapies
Herpesviruses (Acyclovir, Valacyclovir): Phosphorylated by viral thymidine kinase to monophosphate, then by host enzymes to triphosphate, competitively inhibiting viral DNA polymerase.
Influenza (Oseltamivir): Inhibits viral neuraminidase , preventing virion release from infected host cells.
HIV Antiretrovirals: Combinations of NRTIs (tenofovir/emtricitabine), NNRTIs (efavirenz), Protease Inhibitors (darunavir), and INSTIs (dolutegravir/bictegravir).